These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 7745993)

  • 1. Adjuvant effect of low-dose interleukin-2 on antibody response to influenza virus vaccination in healthy elderly subjects.
    Provinciali M; Di Stefano G; Colombo M; Della Croce F; Gandolfi MC; Daghetta L; Anichini M; Della Bitta R; Fabris N
    Mech Ageing Dev; 1994 Dec; 77(2):75-82. PubMed ID: 7745993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 21-winter seasons retrospective study of antibody response after influenza vaccination in elderly (60-85 years old) and very elderly (>85 years old) institutionalized subjects.
    Nunzi E; Iorio AM; Camilloni B
    Hum Vaccin Immunother; 2017 Nov; 13(11):2659-2668. PubMed ID: 28922621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of a novel IL-2-supplemented liposomal influenza vaccine (INFLUSOME-VAC) in nursing-home residents.
    Ben-Yehuda A; Joseph A; Barenholz Y; Zeira E; Even-Chen S; Louria-Hayon I; Babai I; Zakay-Rones Z; Greenbaum E; Galprin I; Glück R; Zurbriggen R; Kedar E
    Vaccine; 2003 Jul; 21(23):3169-78. PubMed ID: 12804845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular and humoral influenza-specific immune response upon vaccination in patients with common variable immunodeficiency and unclassified antibody deficiency.
    Hanitsch LG; Löbel M; Mieves JF; Bauer S; Babel N; Schweiger B; Wittke K; Grabowski P; Volk HD; Scheibenbogen C
    Vaccine; 2016 May; 34(21):2417-2423. PubMed ID: 27055021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of repeated annual influenza vaccination on antibody responses against unchanged vaccine antigens in elderly frail institutionalized volunteers.
    Iorio AM; Camilloni B; Basileo M; Neri M; Lepri E; Spighi M
    Gerontology; 2007; 53(6):411-8. PubMed ID: 17975317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune response to influenza vaccination in institutionalized elderly: effect on different T-cell subsets.
    McElhaney JE; Gravenstein S; Upshaw CM; Hooton JW; Krause P; Drinka P
    Vaccine; 1998 Feb; 16(4):403-9. PubMed ID: 9607063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Safety and immunogenicity of seasonal inactivated influenza vaccine (split virion) and cross-reactive antibody responses to the H7N9 avian influenza virus].
    Guo W; Xu J; Wu J; Zhao S; He H; Shi W; Yu D; Li J; Gao H; Chen J
    Zhonghua Liu Xing Bing Xue Za Zhi; 2014 Aug; 35(8):949-52. PubMed ID: 25376689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
    Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
    Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of MF59 Adjuvant on Induction of Isotype-Switched IgG Antibodies and Protection after Immunization with T-Dependent Influenza Virus Vaccine in the Absence of CD4+ T Cells.
    Ko EJ; Lee YT; Kim KH; Jung YJ; Lee Y; Denning TL; Kang SM
    J Virol; 2016 Aug; 90(15):6976-6988. PubMed ID: 27226368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine.
    van de Sandt CE; Kreijtz JH; Geelhoed-Mieras MM; Vogelzang-van Trierum SE; Nieuwkoop NJ; van de Vijver DA; Fouchier RA; Osterhaus AD; Morein B; Rimmelzwaan GF
    Vaccine; 2014 Sep; 32(43):5614-23. PubMed ID: 25140929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High interleukin-10 production is associated with low antibody response to influenza vaccination in the elderly.
    Corsini E; Vismara L; Lucchi L; Viviani B; Govoni S; Galli CL; Marinovich M; Racchi M
    J Leukoc Biol; 2006 Aug; 80(2):376-82. PubMed ID: 16707559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI).
    Taylor DN; Treanor JJ; Strout C; Johnson C; Fitzgerald T; Kavita U; Ozer K; Tussey L; Shaw A
    Vaccine; 2011 Jul; 29(31):4897-902. PubMed ID: 21596084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral immunization of haemaggulutinin H5 expressed in plant endoplasmic reticulum with adjuvant saponin protects mice against highly pathogenic avian influenza A virus infection.
    Lee G; Na YJ; Yang BG; Choi JP; Seo YB; Hong CP; Yun CH; Kim DH; Sohn EJ; Kim JH; Sung YC; Kim YK; Jang MH; Hwang I
    Plant Biotechnol J; 2015 Jan; 13(1):62-72. PubMed ID: 25065685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.
    Belshe RB; Frey SE; Graham IL; Anderson EL; Jackson LA; Spearman P; Edupuganti S; Mulligan MJ; Rouphael N; Winokur P; Dolor RJ; Woods CW; Walter EB; Chen WH; Turley C; Edwards KM; Creech CB; Hill H; Bellamy AR;
    JAMA; 2014 Oct; 312(14):1420-8. PubMed ID: 25291578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
    Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M
    Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influenza revaccination of elderly travelers: antibody response to single influenza vaccination and revaccination at 12 weeks.
    Buxton JA; Skowronski DM; Ng H; Marion SA; Li Y; King A; Hockin J
    J Infect Dis; 2001 Jul; 184(2):188-91. PubMed ID: 11424016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modest Waning of Influenza Vaccine Efficacy and Antibody Titers During the 2007-2008 Influenza Season.
    Petrie JG; Ohmit SE; Truscon R; Johnson E; Braun TM; Levine MZ; Eichelberger MC; Monto AS
    J Infect Dis; 2016 Oct; 214(8):1142-9. PubMed ID: 27095420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral adjuvants for viral vaccines in humans.
    Ishizaka S; Yoshikawa M; Kitagami K; Tsujii T
    Vaccine; 1990 Aug; 8(4):337-41. PubMed ID: 2396473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of the Microparticle Nanoscale Silicon Dioxide as an Adjuvant To Boost Vaccine Immune Responses against Influenza Virus in Neonatal Mice.
    Russell RF; McDonald JU; Lambert L; Tregoning JS
    J Virol; 2016 May; 90(9):4735-4744. PubMed ID: 26912628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.